IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Pre-Mkt 02-05 09:12:42 EST

0.2105

-0.0063

-2.93%

盘前0.2240

+0.0135+6.41%

09:12 EST

High0.2176	Low0.2105	Vol72.86K
Open0.2161	D1 Closing0.2169	Amplitude3.27%
Mkt Cap3.57M	Tradable Cap3.46M	Total Shares16.97M
T/O15.67K	T/O Rate0.44%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.2105,"timestamp":1770238800000,"preClose":0.21685,"halted":0,"volume":72856,"hourTrading":{"tag":"盘前","latestPrice":0.224,"preClose":0.2105,"latestTime":"09:12 EST","volume":3723,"amount":803.23527681,"timestamp":1770300739968,"change":0.0135,"changeRate":0.064133,"amplitude":0.093112},"delay":0,"changeRate":-0.0292829144569979,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Pre-Mkt","change":-0.00635,"latestTime":"02-05 09:12:42 EST","open":0.2161,"high":0.2176,"low":0.2105,"amount":15669.72058232,"amplitude":0.032742,"askPrice":0.2486,"askSize":100,"bidPrice":0.2101,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.861876,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770301800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.2105,"preHourTrading":{"tag":"盘前","latestPrice":0.224,"preClose":0.2105,"latestTime":"09:12 EST","volume":3723,"amount":803.23527681,"timestamp":1770300739968,"change":0.0135,"changeRate":0.064133,"amplitude":0.093112},"postHourTrading":{"tag":"盘后","latestPrice":0.2236,"preClose":0.2105,"latestTime":"19:58 EST","volume":2725,"amount":604.6521,"timestamp":1770253102893,"change":0.0131,"changeRate":0.062233,"amplitude":0.062233},"volumeRatio":0.21249650740584677,"impliedVol":1.8468,"impliedVolPercentile":0.98},"requestUrl":"/m/hq/s/ITP","defaultTab":"news","newsList":[{"id":"2609998473","title":"Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2609998473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609998473?lang=en_us&edition=fundamental","pubTime":"2026-02-05 00:32","pubTimestamp":1770222764,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Study Overview: Takeda is running a Phase 3 continuation ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4199","BK4211","ISBC","ITP"],"gpt_icon":0},{"id":"2608605362","title":"Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2608605362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608605362?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:00","pubTimestamp":1770210000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  04, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232006/0/en/Bionano-Announces-Publication-from-Sanford-Burnham-Prebys-Medical-Discovery-Institute-Describing-use-of-OGM-to-Detect-Genomic-Alterations-Introduced-by-Gene-Editing-Technologies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2602543576","title":"CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543576?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:36","pubTimestamp":1768224960,"startTime":"0","endTime":"0","summary":"-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216929/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LDL","BK4516","BK4588","LU0251131958.USD","BK4090","CAR","ITP","BK4504","BK4520","LU1720051108.HKD","FXI","SLE","AGT","LU0868494708.USD","LU0868494617.USD","LU1720051017.SGD","LU2106854487.HKD","LU0251142724.SGD","LU1917777945.USD","BK4199","LU1548497426.USD","BK4153","LU2023250504.SGD","LU1974910355.USD","TG","BK4022","CRSP","SCD","BK4149","LU2264538146.SGD","LU0942090050.USD","IE00BD6J9T35.USD","BK4230","BK4077","LU2237438978.USD","LU0048573561.USD","LU2357305700.SGD","BK4611","LU1861559042.SGD","BK4532","CAT","BK4597","BK4556","IE00BSNM7G36.USD","LU0963586101.USD","LU0742534661.SGD","LU1861558580.USD","LU1988902786.USD","BK4139"],"gpt_icon":0},{"id":"2602108435","title":"Press Release: Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602108435","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602108435?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 12, 2026  -- Bionano Genomics, Inc.  today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025.Fourth Quarter 2025 Preliminary, Unaudited Financial and Business Results. -- Total revenue is expected to be in the range of $7.8 million to $8.0. million, which is at the upper end of guidance and represents a decrease. in the range of 2% to 4% year-over-year.-- Nanochannel array flowcells sold in the fourth quarter of 2025 is. -- Total revenue is expected to be in the range of $28.4 million to $28.6. represents a decrease in the range of 7% to 8% year-over-year.resulted in an installed base of 387 OGM systems at year-end 2025,Cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, of which $10.3 million is subject to certain restrictions.Bionano is in the process of completing its customa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4575","BK4099","BK4199","03160","BK4604","BK4585","BK4555","BK4588","BNGO","ITP","TM"],"gpt_icon":0},{"id":"2602595531","title":"argenx Highlights 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595531","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602595531?lang=en_us&edition=fundamental","pubTime":"2026-01-12 14:00","pubTimestamp":1768197600,"startTime":"0","endTime":"0","summary":"Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales  VYVGART impact continues with approximately 19,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216531/0/en/argenx-Highlights-2026-Strategic-Priorities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","BK4208","LU2500361329.USD","BK4187","BK4585","BK4550","LU1003077747.HKD","ITP","GD","LU1894683348.USD","LU0738911758.USD","CMS","LU0661504455.SGD","LU2637428348.USD","BK4516","LU0170899867.USD","LU0553294199.USD","BK4199","LU0545039389.USD","SMA","LU2346227817.USD","BK4588","BK4217","BK4566","LU0949170772.SGD"],"gpt_icon":0},{"id":"2601698403","title":"Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601698403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601698403?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215211/0/en/Climb-Bio-Announces-Pipeline-Progress-and-Strategic-Priorities-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","BK4077","LU2065732104.USD","IND","SLE","LU2463526074.USD","BK4109","BK4097","PRGS","ASH"],"gpt_icon":0},{"id":"1163901175","title":"Hangzhou's \"Six Little Dragons\" See Another IPO Emerge","url":"https://stock-news.laohu8.com/highlight/detail?id=1163901175","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163901175?lang=en_us&edition=fundamental","pubTime":"2026-01-05 15:41","pubTimestamp":1767598901,"startTime":"0","endTime":"0","summary":"Investing hinges on the insights of Golden Kirin analyst reports, which offer authority, professionalism, timeliness, and comprehensiveness to help you uncover potential thematic opportunities! The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"gpt_icon":0},{"id":"2591301690","title":"argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2591301690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591301690?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:00","pubTimestamp":1765778400,"startTime":"0","endTime":"0","summary":"15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205093/0/en/argenx-Provides-Update-on-UplighTED-Studies-of-Efgartigimod-SC-in-Thyroid-Eye-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2590287346","title":"Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2590287346","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590287346?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283400,"startTime":"0","endTime":"0","summary":"Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202247/0/en/Novartis-ianalumab-significantly-extends-disease-control-in-patients-with-immune-thrombocytopenia-with-only-four-once-monthly-doses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","ASH","LU2463526074.USD","ITP","BK4077","BK4109","BK4110","SLE","BK4199"],"gpt_icon":0},{"id":"2588049548","title":"Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049548","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588049548?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198844/0/en/Final-2026-Clinical-Lab-Fee-Schedule-Indicates-a-47-Increase-in-Payment-Determination-for-the-Category-I-CPT-Code-for-OGM-use-in-Hematologic-Malignancies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","CMS","LU1894683264.USD","LU2346227817.USD","CPT","LU1894683348.USD","LU0545039389.USD","LU1003077747.HKD","BK4208","LU0738911758.USD","BK4588","LU2500361329.USD","LU0949170772.SGD","ITP","LU0661504455.SGD","BK4199","BK4585","LU2637428348.USD","LU0553294199.USD"],"gpt_icon":0},{"id":"2586441294","title":"Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2586441294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586441294?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:15","pubTimestamp":1764051300,"startTime":"0","endTime":"0","summary":"Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings off","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194022/0/en/Novartis-data-underscore-pioneering-scientific-innovation-in-Hematology-and-Oncology-at-ASH-and-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","DDFS","ITP","BK4590","BK4581","BK4144","BK4199","BK4211","ASC","BK4585","ET","BK4195","IS","BK4097","ASH","OS","LU2463526074.USD","BC","EBC","BK4561","BK4109","BK4588","FUL","BK4190"],"gpt_icon":0},{"id":"2583154511","title":"Press Release: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583154511","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583154511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 13, 2025  -- Bionano Genomics, Inc.  today reported financial results for the third quarter ended September 30, 2025.\"Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in the third quarter and year-to-date validates this strategic shift and demonstrates our turn toward sustainable growth as our business stabilizes. This quarter we delivered sustained margins, disciplined operating expense management, and increased utilization from routine users. We continue to see strong momentum in our key geographies and expanding utilization in new regions, including Japan, where researchers are leveraging optical genome mapping  to address complex questions in genetics. These developments strengthen our confidence in Bionano's long-term growth trajectory,\" commented Erik Holmlin, PhD, president and CEO of Bionano.For the thre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2500361329.USD","LU0661504455.SGD","ITP","BK4215","LU0738911758.USD","BK4208","BNGO","LU0553294199.USD","CPT","LU1894683348.USD","BK4097","BK4121","CMS","BK4585","LU2346227817.USD","PRGS","LU2065732104.USD","BK4199","LU1003077747.HKD","BK4588","BK4575","LU0949170772.SGD","LU1894683264.USD","LU2637428348.USD","LU0545039389.USD"],"gpt_icon":0},{"id":"2581095496","title":"Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095496?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  06, 2025  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182538/0/en/Bionano-Announces-Publication-Showing-OGM-Can-Overcome-Key-Limitations-of-Targeted-RNA-Seq-for-Cytogenetic-Investigation-in-Acute-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","RNA","BK4588","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2581095232","title":"Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095232?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:01","pubTimestamp":1762430460,"startTime":"0","endTime":"0","summary":"PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026  Clinical tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182420/0/en/Climb-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2237443622.USD","IE00BHPRN162.USD","IE00BFXG1179.USD","ITP","LU2746668974.SGD","IE00BZ1G4Q59.USD","LU0149725797.USD","IE00B1BXHZ80.USD","LU2237443978.SGD","CMC","LU2237443895.HKD","BK4077","LU0170899867.USD","LU0882574139.USD","LU0267386448.USD","IE00BKVL7J92.USD","BK4006","LU1363072403.SGD","LU2746668461.USD","LU0971096721.USD","LU2237443549.SGD","BK4199","LU2237443382.USD","SLE"],"gpt_icon":0},{"id":"2580323725","title":"HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2580323725","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580323725?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:00","pubTimestamp":1762128000,"startTime":"0","endTime":"0","summary":"— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3178821/0/en/HUTCHMED-Highlights-Pipeline-and-Business-Progress-at-R-D-Updates-Event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","LU2065732104.USD","BK4211","BK4195","ITP","BK4097","BK1588","PFS","00013","PRGS","BK4199"],"gpt_icon":0},{"id":"2580202499","title":"IT Tech Packaging Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580202499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580202499?lang=en_us&edition=fundamental","pubTime":"2025-11-01 00:02","pubTimestamp":1761926561,"startTime":"0","endTime":"0","summary":"IT Tech Packaging Inc. held its 2025 Annual General Meeting of Stockholders on October 31, 2025. At the meeting, two directors were elected to the Board of Directors. Stockholders also ratified the appointment of GGF CPA LTD. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the adoption of the IT Tech Packaging, Inc. 2025 Omnibus Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IT Tech Packaging Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 31, 2025, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL5Q97cr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"gpt_icon":0},{"id":"2579571167","title":"argenx Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579571167","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579571167?lang=en_us&edition=fundamental","pubTime":"2025-10-30 14:00","pubTimestamp":1761804000,"startTime":"0","endTime":"0","summary":"$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any bi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177052/0/en/argenx-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4546","ITP","LU0170899867.USD","BK4208","BK4516","BK4585","LU0738911758.USD","BK4563","BK4187","PFS","SMA","LU2346227817.USD","BK4195","BK4139","LU0553294199.USD","APM","LU1894683264.USD","BK4550","IMNM","BK4199","BK4161","LU2637428348.USD","LU0545039389.USD","LU2500361329.USD","BK4006","AMR","LU1003077747.HKD","CMS","BK4217","DM","BK4588","BK4566","LU0661504455.SGD","BK4211","LU1894683348.USD","GD","LU0949170772.SGD"],"gpt_icon":0},{"id":"2579900527","title":"Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2579900527","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579900527?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:30","pubTimestamp":1761748200,"startTime":"0","endTime":"0","summary":"NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1Data showed consistentimprovementsacross secondary outcome measures, and a f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176619/0/en/Novartis-ianalumab-first-drug-to-reduce-disease-activity-and-patient-burden-in-Sj%C3%B6gren-s-disease-Phase-III-trials.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","SLE","BK4077","BK4134","BK4110","III","ITP","BK4199"],"gpt_icon":0},{"id":"2578481989","title":"Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2578481989","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578481989?lang=en_us&edition=fundamental","pubTime":"2025-10-28 14:00","pubTimestamp":1761631200,"startTime":"0","endTime":"0","summary":"Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175089/0/en/Novartis-delivers-solid-sales-and-core-operating-income-growth-with-strong-pipeline-progress-in-Q3-reaffirms-FY-2025-guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMR","BK4561","BK4581","BK4585","BK4590","ITP","BK4144","BK4199","USD","ET","BK4588"],"gpt_icon":0},{"id":"2578774776","title":"Climb Bio’s Promising ITP Study: A Potential Game-Changer for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578774776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578774776?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:17","pubTimestamp":1761607072,"startTime":"0","endTime":"0","summary":"Climb Bio, Inc. (($CLYM)) announced an update on their ongoing clinical study. Study Overview: Climb Bio, Inc. is conducting a Phase 1b/2a study ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/climb-bios-promising-itp-study-a-potential-game-changer-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/climb-bios-promising-itp-study-a-potential-game-changer-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","ITP","BK4199"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":-0.0445},{"period":"1month","weight":-0.1337},{"period":"3month","weight":-0.2005},{"period":"6month","weight":0.012},{"period":"1year","weight":-0.3422},{"period":"ytd","weight":-0.0375}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":0.003139},{"month":3,"riseRate":0.1875,"avgChangeRate":-0.021818},{"month":4,"riseRate":0.3125,"avgChangeRate":0.040688},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.119651},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.03945},{"month":7,"riseRate":0.466667,"avgChangeRate":-0.042617},{"month":8,"riseRate":0.125,"avgChangeRate":-0.076512},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}